Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | PLAT | P00750 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 7/20 | 0.49 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10606515 | 0.83 | ALOX5 (0.67) | ALOX5CYP3A4PLAUPLATMRGPRX4 | |
| SCHEMBL22703560 | 0.81 | ALOX5 (0.65) | ALOX5CYP3A4PLAUPLATMRGPRX4 | |
| SCHEMBL4079350 | 0.81 | ALOX5 (0.65) | ALOX5CYP3A4PLAUPLATMRGPRX4 | |
| SCHEMBL38662923 | 0.81 | ALOX5 (0.65) | ALOX5CYP3A4PLAUPLATMRGPRX4 | |
| SCHEMBL51460 | 0.79 | ALOX5 (1.00) | ALOX5CYP3A4MRGPRX4MAOBMAOA | |
| SCHEMBL28662350 | 0.78 | ALOX5 (0.89) | ALOX5CYP3A4MRGPRX4MAOBMAOA | |
| SCHEMBL6414966 | 0.78 | MRGPRX4 (0.60) | ALOX5PLAUPLATMRGPRX4MAOB | |
| SCHEMBL22703183 | 0.78 | ALOX5 (0.59) | ALOX5CYP3A4PLAUPLATMRGPRX4 | |
| SCHEMBL4483973 | 0.78 | ALOX5 (0.59) | ALOX5CYP3A4PLAUPLATMRGPRX4 | |
| SCHEMBL9127192 | 0.77 | ALOX5 (0.73) | ALOX5CYP3A4MRGPRX4MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258910-A1 | benzo[1,3]dioxol-5-yl-carbamic acid 6-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester and benzo[1,3]dioxol-5-yl-carbamic acid 8-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester; | IRM LLC (BM) | 2009-10-15 | — | — | US | disclosed |
| US-7569593-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2009-08-04 | — | — | US | disclosed |
| CN-100455579-C | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2009-01-28 | — | — | CN | disclosed |
| EP-1670780-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-12-17 | — | — | EP | disclosed |
| CN-1860111-A | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2006-11-08 | — | — | CN | disclosed |
| EP-1670780-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-06-21 | — | — | EP | disclosed |
| US-20050209285-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-09-22 | — | — | US | disclosed |
| WO-2005030151-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (US) | 2005-04-07 | — | — | WO | disclosed |
| EP-1090012-A4 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2005-04-06 | — | — | EP | disclosed |
| US-6562823-B1 | Inhibition of farnesyl-protein transferase has been shown to block the growth of Ras-transformed cells in soft agar | MERCK & CO., INC. | 2003-05-13 | — | — | US | disclosed |
| EP-1090012-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000001702-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258910-A1 | benzo[1,3]dioxol-5-yl-carbamic acid 6-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester and benzo[1,3]dioxol-5-yl-carbamic acid 8-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester; | PDGFRA, RAF1, FLT1 | ALOX5 3539/4885CYP3A4 2880/4885PLAU 3885/4885 |
| US-20050209285-A1 | Compounds and compositions as protein kinase inhibitors | LCK, RAF1, MAP3K1 | ALOX5 4262/4885CYP3A4 3534/4885PLAU 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.